株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

医療機器トップ企業シリーズ:体外診断 (IVD) 分野の有力企業 (2019年~2029年)

Medical Devices Leader Series - Top In Vitro Diagnostics (IVD) Companies 2019-2029: Danaher Corporation, Abbott Laboratories, Bio-Rad Laboratories, Roche, Siemens AG, Sysmex, Other Companies

発行 Visiongain Ltd 商品コード 264338
出版日 ページ情報 英文 204 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=147.19円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

Back to Top
医療機器トップ企業シリーズ:体外診断 (IVD) 分野の有力企業 (2019年~2029年) Medical Devices Leader Series - Top In Vitro Diagnostics (IVD) Companies 2019-2029: Danaher Corporation, Abbott Laboratories, Bio-Rad Laboratories, Roche, Siemens AG, Sysmex, Other Companies
出版日: 2019年05月14日 ページ情報: 英文 204 Pages
概要

当レポートでは、世界の体外診断 (IVD) 市場における代表的企業について分析し、各企業の近年の業績動向や今後の見通し、主力製品/サービス、各企業の競争優位/劣位分野、近年の事業展開状況 (M&Aほか) などを調査すると共に、業界全体の構造や動向見通し、主な市場促進・抑制要因といった情報を取りまとめてお届けいたします。

第1章 レポートの概要

第2章 体外診断 (IVD) のイントロダクション

  • IVD市場:最新情勢
  • IVD検査とは
  • IVDの分類
    • 米国の分類
    • 欧州 (EC) の分類
    • IVD市場における規制上の問題
  • IVD検査の種類
    • ポイントオブケア (POC) 診断
    • 臨床化学検査
    • 微生物検査
    • 血液検査
    • 免疫化学検査
    • 遺伝子検査
  • 体外診断市場全体の収益予測
    • 市場推進要因
    • 市場抑制要因
    • IVD産業の将来性
  • 企業比較
    • 細分化された市場
    • IVD市場における主要企業

第3章 米国の代表的な体外診断 (IVD) 企業

  • Danaher Corporation
    • 売上高および近年の業績の分析
    • 主要製品・サービス
    • 研究開発 (R&D)/生産能力
    • 市場収益額の予測 (今後11年間分)
    • 近年の企業合併・買収 (M&A)/事業展開状況、など
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • Becton, Dickinson and Company
  • Thermo Fisher Scientific

第4章 欧州の代表的な体外診断 (IVD) 企業

  • Hoffmann-La Roche Ltd.
  • Siemens AG
  • bioMerieux S.A.

第5章 日本の代表的な体外診断 (IVD) 企業

  • シスメックス
  • アークレイ

第6章 体外診断 (IVD) 分野の新興企業

  • パイプラインおよびその他の企業の概要
  • その他の有望なIVD企業
  • Dako (Agilent Technologies)
  • Genomic Health, Inc.
  • Laboratory Corporation of America (LabCorp)
  • MDxHealth, Inc.
  • Myriad Genetics, Inc.
    • Myriad RBM
  • QIAGEN N.V.

第7章 その他のIVD企業

  • Hologic, Inc.
  • Bayer AG
  • Transasia Bio-Medicals Ltd.
  • PerkinElmer, Inc.
  • DiaSorin S.p.A.
  • Koninklijke Philips N.V.
  • Illumina, Inc.
  • Kem-en-tec Diagnostics A/S

第8章 結論

図表

List of Tables

  • Table 2.1 IVD Revenues ($bn) and Market Shares (%) by Class, 2017-2018
  • Table 2.2 Advantages and Disadvantages of POC Diagnostics
  • Table 2.3 IVD Tests: Overall World Market and Submarket Revenue Forecasts ($bn), 2018, 2019, 2024 & 2029
  • Table 2.4 Leading Manufacturers: IVD Market Share (%), 2018
  • Table 2.5 Leading Companies in the IVD Market: Net Sales ($bn) and Market Shares (%), 2018
  • Table 3.1 Danaher: Key Facts
  • Table 3.2 Danaher: Net Sales ($bn) and Revenue Shares (%) by Business Segment, 2017
  • Table 3.3 Danaher: Life Sciences & Diagnostics Revenue ($bn), AGR (%), 2015-2017
  • Table 3.4 Danaher: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
  • Table 3.5 Abbott: Key Facts
  • Table 3.6 Abbott: Net Sales ($bn) and Revenue Shares (%) by Business Segment, 2017
  • Table 3.7 Abbott: Revenues ($bn) and Revenue Shares (%) by Geographical Region, 2017
  • Table 3.8 Abbott: Diagnostics Revenue ($bn), AGR (%), 2015-2017
  • Table 3.9 Abbott: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
  • Table 3.10 Bio-Rad: Key Facts
  • Table 3.11 Bio-Rad: Clinical Diagnostics Revenue ($bn), AGR (%) 2015-2017
  • Table 3.12 Bio-Rad: IVD Revenue Forecast ($bn), Growth (%), CAGR (%), Market Share (%) 2019-2029
  • Table 3.13 BD: Key Facts
  • Table 3.14 Becton Dickinson: Net Sales ($bn) and Revenue Shares (%) by Sector, 2017
  • Table 3.15 BD: Diagnostics Revenue ($bn), AGR (%) 2015-2017
  • Table 3.16 BD: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
  • Table 3.17 Thermo Fisher: Key Facts
  • Table 3.18 Thermo Fisher: IVD Sales ($bn), AGR (%), 2015-2017
  • Table 3.19 Thermo Fisher: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
  • Table 4.1 Roche: Key Facts
  • Table 4.2 Roche: Revenue ($bn) and Revenue Shares (%) by Sector, 2017
  • Table 4.3 Roche Diagnostics: Revenue ($bn) and Revenue Shares (%) by Sector, 2017
  • Table 4.4 Roche Diagnostics: Marketed Diagnostic Products
  • Table 4.5 Roche: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
  • Table 4.6 Siemens: Key Facts
  • Table 4.7 Siemens: Revenue ($bn) and Revenue Shares (%) by Sector, 2017
  • Table 4.8 Siemens: Revenue ($bn) and Revenue Shares (%) by Region, 2017
  • Table 4.9 Siemens: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
  • Table 4.10 bioMérieux: Key Facts
  • Table 4.11 bioMérieux: Revenue ($bn) and Revenue Shares (%) by Sector, 2017
  • Table 4.12 bioMérieux: Clinical Applications Revenue ($bn) and Revenue Shares (%) by Sector, 2017
  • Table 4.13 bioMérieux: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
  • Table 5.1 Sysmex: Key Facts
  • Table 5.2 Sysmex: Revenue ($bn) by Sector, 2017
  • Table 5.3 Sysmex: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
  • Table 5.4 Arkray: Key Facts
  • Table 5.5 Arkray: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2019-2029
  • Table 6.1 Agilent: Revenue ($bn) and Revenue Shares (%) by Sector, 2017
  • Table 6.2 Dako: Marketed Diagnostic Products, 2017
  • Table 6.3 Genomic Health: Revenue ($m) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 6.4 Genomic Health: R&D Expense ($m) and R&D Expense as a Percentage of Sales (%), 2013-2017
  • Table 6.5 LabCorp: Revenues ($bn) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 6.6 Selected List of LabCorp's Menu of Diagnostic Products, 2017
  • Table 6.7 MDxHealth: Revenue ($m) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 6.8 MDxHealth: In Vitro Diagnostics Pipeline, 2017
  • Table 6.9 Myriad: Revenue ($m) and Revenue Shares (%) by Sector, 2017
  • Table 6.10 Myriad Molecular Diagnostics: Revenue ($m) and Revenue Shares (%) by Product, 2017
  • Table 6.11 Myriad Molecular Diagnostics: Revenue ($m) and Revenue Shares (%) by Sector, 2017
  • Table 6.12 Myriad: Biomarker Product Portfolio, 2017
  • Table 6.13 Myriad: Diagnostic Products, 2017
  • Table 6.14 QIAGEN: Revenue ($m) and Revenue Shares (%) by Customer Class, 2017
  • Table 6.15 QIAGEN: Revenue ($m) and Revenue Shares (%) by Region, 2017
  • Table 6.16 QIAGEN: Selected List of Co-development Projects
  • Table 6.17 QIAGEN: Selected Marketed Diagnostic Products
  • Table 6.18 QIAGEN: Recent M&A Activity
  • Table 6.19 Other Companies Operating in the IVD Market, 2018
  • Table 7.1 Hologic, Inc.: Key Facts
  • Table 7.2 Hologic, Inc.: Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 7.3 Hologic, Inc.: Product Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 7.4 Hologic, Inc.: Clinical Diagnostics Revenue ($bn), AGR (%) 2015-2017
  • Table 7.5 Bayer AG: Key Facts, 2017
  • Table 7.6 Bayer AG: Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 7.7 Transasia Bio-Medicals Ltd: Key Facts, 2017
  • Table 7.8 PerkinElmer, Inc.: Key Facts, 2017
  • Table 7.9 PerkinElmer, Inc.: Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 7.10 PerkinElmer, Inc.: Product Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 7.11 PerkinElmer, Inc.: Clinical Diagnostics Revenue ($bn), AGR (%) 2015-2017
  • Table 7.12 DiaSorin: Key Facts, 2017
  • Table 7.13 DiaSorin: Revenue ($m) and Revenue Shares (%) by Geography, 2017
  • Table 7.14 Koninklijke Philips N.V.: Key Facts, 2017
  • Table 7.15 Koninklijke Philips N.V.: Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 7.16 Koninklijke Philips N.V.: Diagnosis & Treatment Revenue ($bn), AGR (%) 2015-2017
  • Table 7.17 Koninklijke Philips N.V.: Diagnosis & Treatment Product Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 7.18 Illumina, Inc.: Key Facts
  • Table 7.19 Illumina, Inc.: Revenue ($bn) and Revenue Shares (%) by Reporting Segment, 2017
  • Table 7.20 Kem-en-tec Diagnostics A/S: Key Facts
  • Table 8.1 Leading IVD Manufacturers by Company Type, 2018

List of Figures

  • Figure 2.1 IVD Market ($bn) by Class 2018
  • Figure 2.2 IVD: Overall Market ($bn) Forecast, 2018, 2019, 2024 & 2029
  • Figure 2.3 IVD Market: Drivers and Restraints, 2019-2029
  • Figure 2.4 Leading Companies in the IVD Market: Net Sales ($bn), 2018
  • Figure 2.5 Leading Companies in the IVD Market: (% Share), 2018
  • Figure 3.1 Danaher: Net Sales ($bn) by Business Segment, 2017
  • Figure 3.2 Danaher: Revenue Shares (%) by Business Segment, 2017
  • Figure 3.3 Danaher: IVD Revenue ($bn) Forecast, AGR (%), 2019-2029
  • Figure 3.4 Danaher: IVD Market Share (%), 2019-2029
  • Figure 3.5 Abbott: Net Sales ($bn) by Business Segment, 2017
  • Figure 3.6 Abbott: Revenue Shares (%) by Business Segment, 2017
  • Figure 3.7 Abbott: Revenues ($bn) by Region, 2017
  • Figure 3.8 Abbott: Revenue Shares (%) by Region, 2017
  • Figure 3.9 Abbott: IVD Revenue ($bn) Forecast, AGR (%), 2019-2029
  • Figure 3.10 Abbott: IVD Market Share (%), 2019-2029
  • Figure 3.11 Bio-Rad: Historical Diagnostics Revenues ($bn) 2014-2017
  • Figure 3.12 Bio-Rad: Revenue Shares (%) by Business Segment, 2017
  • Figure 3.13 Bio-Rad: Revenue Shares (%) by Region, 2017
  • Figure 3.14 Bio-Rad: IVD Revenue Forecast ($bn), AGR (%), 2019-2029
  • Figure 3.15 Bio-Rad: IVD Market Share (%), 2019-2029
  • Figure 3.16 Becton Dickinson: Revenue Shares (%) by Sector, 2017
  • Figure 3.17 BD: Company Revenue ($bn), 2015-2017
  • Figure 3.18 BD IVD Revenue Forecast ($bn), AGR (%), 2019-2029
  • Figure 3.19 BD: IVD Market Share (%), 2019-2029
  • Figure 3.20 Thermo Fisher: IVD Net Sales ($bn), 2015-2017
  • Figure 3.21 Thermo Fisher: Revenue Shares (%) by Sector, 2017
  • Figure 3.22 Thermo Fisher: IVD Revenue ($bn) Forecast, AGR (%), 2019-2029
  • Figure 3.23 Thermo Fisher: IVD Market Share (%), 2019-2029
  • Figure 3.24 Thermo Fisher: Mergers & Acquisitions
  • Figure 4.1 Roche: Revenues ($bn) by Sector, 2017
  • Figure 4.2 Roche: Revenue Shares (%) by Sector, 2017
  • Figure 4.3 Roche Diagnostics: Revenues ($bn) by Sector, 2017
  • Figure 4.4 Roche Diagnostics: Revenue Shares (%) by Sector, 2017
  • Figure 4.5 Roche: IVD Revenue ($bn), AGR (%), Forecast, 2019-2029
  • Figure 4.6 Roche: IVD Market Share (%), 2019-2029
  • Figure 4.7 Siemens: Revenue Shares (%) by Sector, 2017
  • Figure 4.8 Siemens Healthcare: Revenue Shares (%) by Region, 2017
  • Figure 4.9 Siemens: IVD Revenue ($bn), AGR (%), Forecast 2019-2029
  • Figure 4.10 Siemens: IVD Market Share (%), 2019-2029
  • Figure 4.11 bioMérieux: Revenue ($bn) by Sector, 2017
  • Figure 4.12 bioMérieux: Revenue Shares (%) by Sector, 2017
  • Figure 4.13 bioMérieux: Clinical Applications Revenue ($bn) by Sector, 2017
  • Figure 4.14 bioMérieux: Clinical Applications Revenue Shares (%) by Sector, 2017
  • Figure 4.15 bioMérieux: IVD Revenue ($bn), AGR (%), Forecast, 2019-2029
  • Figure 4.16 bioMérieux: IVD Market Share (%), 2019-2029
  • Figure 5.1 Sysmex: Revenues ($bn) by Sector, 2017
  • Figure 5.2 Sysmex: Revenue Shares (%) by Sector, 2017
  • Figure 5.3 Sysmex: Net Sales (%) by Geographical Region, 2017
  • Figure 5.4 Sysmex: IVD Revenue ($bn) Forecast, AGR (%), 2019-2029
  • Figure 5.5 Sysmex: IVD Market Share (%), 2019-2029
  • Figure 5.6 Arkray: IVD Revenue ($bn) Forecast, (AGR %), 2019-2029
  • Figure 5.7 Arkray: IVD Market Share (%), 2019-2029
  • Figure 6.1 Agilent: Revenue ($bn) by Sector, 2017
  • Figure 6.2 Dako: Revenue Shares (%) by Sector, 2017
  • Figure 6.3 Genomic Health: Historical Revenues ($m) and Net Income ($m), 2013-2017
  • Figure 6.4 Genomic Health: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 6.5 Genomic Health: Historical R&D Expense ($m) and R&D as a Percentage of Net Sales (%), 2013-2017
  • Figure 6.6 LabCorp: Historical Revenue ($bn), Profit ($bn), 2013-2017
  • Figure 6.7 LabCorp: Revenues ($bn) by Reporting Segment, 2017
  • Figure 6.8 LabCorp: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 6.9 MDxHealth: Revenues ($m) by Reporting Segment, 2017
  • Figure 6.10 MDxHealth: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 6.11 Myriad: Historical Net Revenues ($m), 2013-2017
  • Figure 6.12 Myriad: Revenue Shares (%) by Sector, 2017
  • Figure 6.13 Myriad Molecular Diagnostics: Revenue Shares (%) by Product, 2017
  • Figure 6.14 Myriad Molecular Diagnostics: Revenue Shares (%) by Sector, 2017
  • Figure 6.15 Myriad: Historical R&D Investments ($m), 2013-2017
  • Figure 6.16 QIAGEN: Historical Revenue ($bn), Net Income ($bn), 2013-2017
  • Figure 6.17 QIAGEN: Revenues ($m) by Customer Class, 2017
  • Figure 6.18 QIAGEN: Revenue Shares (%) by Customer Class, 2017
  • Figure 6.19 QIAGEN: Revenue Shares (%) by Region, 2017
  • Figure 6.20 QIAGEN: Historical R&D Expense ($m) and R&D Expense as a Percentage of Net Revenue (%), 2013-2017
  • Figure 7.1 Hologic, Inc.: Historical Revenues ($bn) and Net Income ($bn), 2013-2017
  • Figure 7.2 Hologic, Inc.: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 7.3 Hologic, Inc.: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 7.4 Hologic, Inc.: Revenue Shares (%) by Region, 2017
  • Figure 7.5 Hologic, Inc.: Diagnostics Revenue Shares (%), 2017
  • Figure 7.6 Bayer AG: Historical Revenues ($bn) and Net Income ($bn), 2013-2017
  • Figure 7.7 Bayer AG: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 7.8 Bayer AG: Revenue Shares (%) by Region, 2017
  • Figure 7.9 PerkinElmer, Inc.: Historical Revenues ($bn), 2013-2017
  • Figure 7.10 PerkinElmer, Inc.: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 7.11 PerkinElmer, Inc.: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 7.12 PerkinElmer, Inc.: Revenue Shares (%) by Region, 2017
  • Figure 7.13 PerkinElmer, Inc.: Diagnostics Revenue Shares (%), 2017
  • Figure 7.14 DiaSorin: Historical Revenues ($m), 2013-2017
  • Figure 7.15 DiaSorin: Revenue Shares (%) by Region, 2017
  • Figure 7.16 Koninklijke Philips N.V.: Historical Revenues ($bn), 2013-2017
  • Figure 7.17 Koninklijke Philips N.V.: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 7.18 Koninklijke Philips N.V.: Revenue Shares (%) by Region, 2017
  • Figure 7.19 Koninklijke Philips N.V.: Diagnosis & Treatment Revenue ($b), 2017
  • Figure 7.20 Koninklijke Philips N.V.: Diagnosis & Treatment Revenue ($bn) by Product, 2017
  • Figure 7.21 Koninklijke Philips N.V.: Diagnosis & Treatment Revenue Shares (%) by Product, 2017
  • Figure 7.22 Illumina, Inc.: Historical Revenues ($bn) and Net Income ($bn), 2013-2017
  • Figure 7.23 Illumina, Inc.: Revenue Shares (%) by Reporting Segment, 2017
  • Figure 7.24 Illumina, Inc.: Revenue Shares (%) by Region, 2017
  • Figure 8.1 IVD Market: Overall World Revenue ($bn), (AGR%) 2019-2029
  • Figure 8.2 IVD Market: Revenue ($bn) Forecasts, 2018, 2019, 2024, and 2029

COMPANIES LISTED:

  • AB SCIEX
  • Abbott Laboratories
  • AbD Serotec
  • Agilent Technologies
  • Alacris Theranostics GmbH
  • Alere
  • Amoy Diagnostics Co. Ltd
  • Analytical Informatics, Inc.
  • Arca biopharma
  • ARGENE
  • Arkray, Inc.
  • Astute Medical
  • Bayer
  • Beckman Coulter
  • Becton Dickinson
  • BioFire Diagnostics, LLC
  • BioMarin Pharmaceutical Inc.
  • bioMérieux
  • Bio-Rad Laboratories
  • Bristol-Myers Squibb
  • C. R. Bard, Inc.
  • Calbiotech Group of Companies
  • CareFusion
  • Carmel Pharma AB
  • Cartagenia
  • Cell Signaling Technology
  • Celldex Therapeutics
  • Cellestis Ltd.
  • Cellular Research
  • Cephalon
  • Cepheid
  • Chugai Pharmaceuticals
  • Clearbridge BioMedics
  • Constitutional Medical, Inc. (CMI)
  • Crescendo Bioscience
  • Dako
  • Danaher
  • DiaMed Holding
  • Diasis Diagnostik Sistemler Ticaret Ve Sanayi A.S.
  • DiaSorin S.p.A.
  • Diesse
  • Dionex
  • Eli Lilly
  • Epitomics
  • EQT
  • Erba Diagnostics Mannheim GmbH Group
  • Erba -Transasia
  • eScreen Inc.
  • EskoArtwork
  • European Commission (EC)
  • Fast Track Diagnostics (FTD)
  • Focus Diagnostics
  • Food and Drug Administration (FDA)
  • Furuno Electric Co., Ltd.
  • GenCell Biosystems
  • Genentech
  • Genetic Analysis
  • Genomic Health
  • Genzyme Genetics
  • GlaxoSmithKline (GSK)
  • GnuBIO Inc.
  • Grifols
  • Haliodx
  • Hologic, Inc.
  • Illumina, Inc.
  • Inostics Inc.
  • Institut Merieux
  • InterMune
  • Ipsogen S.A.
  • IRIS International
  • JEOL Ltd.
  • Johnson & Johnson
  • Kappa Biosystems, Inc.
  • Katakura Industries Co., Ltd.
  • Kem-En-Tec Diagnostics
  • Knome, Inc.
  • Koninklijke Philips N.V.
  • LabIndia
  • Laboratory Corporation of America (LabCorp)
  • Laetus
  • Leica Microsystems
  • Life Technologies
  • LipoScience, Inc.
  • Lyon Civil Hospitals
  • Maxmat SA
  • MDS
  • MDxHealth
  • Medica
  • Merck & Co.
  • Merck KGaA
  • Monogram Biosciences
  • MorphoSys AG
  • Myriad Genetics
  • Navman Wireless
  • Nobel Biocare
  • NovioGendix Holding B.V.
  • Oncomed
  • Oxford University
  • Pall
  • Pasteur Sanofi Diagnostics
  • PerkinElmer, Inc.
  • Pfizer
  • Phadia
  • Pharma Mar
  • Phenomenex
  • PreAnalytiX GmbH
  • Propel Labs
  • QIAGEN
  • Quest Diagnostics
  • Remote Diagnostic Technologies (RDT)
  • Roche
  • Rules-Based Medicine Inc.
  • Schering Plough
  • Seahorse Bioscience
  • Siemens AG
  • Siemens Healthcare GmbH
  • Siemens Healthineers
  • Sividon Diagnostics
  • St. Jude Medical
  • Sysmex
  • Sysmex Corporation
  • Sysmex Inostics GmBH
  • Thermo Fisher
  • Thermo Fisher Scientific
  • TOA Corporation
  • TOA Medical Electronics
  • Tocagen
  • Transasia Bio-Medicals Ltd.
  • Tulip Diagnostics Private Ltd.
  • Unisensor
  • Van Andel Research Institute
  • Vanadis Diagnostics, AB
  • Ventana
  • ViiV Healthcare
  • VSS Monitoring
  • XOS
  • X-Rite
目次
Product Code: PHA0420

The global in vitro diagnostics (IVD) market is estimated to have reached $69.2bn in 2018. The largest sector of the IVD market in 2018 was point of care diagnostics segment, generating sales of $19.4bn in 2018, which accounted for 28.0% of overall IVD sales.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 204-page report you will receive 180 charts - all unavailable elsewhere.

The 204-page report provides clear detailed insight into the leading in vitro diagnostics (IVD) companies. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

In Vitro Diagnostics (IVD) revenues in 2017 and 2018 by Class:

  • Point-of-Care
  • Clinical Chemistry
  • Immunochemistry
  • Hematology
  • Microbiology
  • Genetic Testing
  • Others

In Vitro Diagnostics (IVD) revenue forecast for 2019, 2024 and 2029 by Class:

  • Point-of-Care
  • Clinical Chemistry
  • Immunochemistry
  • Hematology
  • Microbiology
  • Genetic Testing
  • Others

This report profiles and discusses the selected leading in vitro diagnostics (IVD) companies:

  • Abbott Laboratories
  • Arkray, Inc.
  • Becton, Dickinson and Company (BD)
  • bioMérieux SA
  • Bio-Rad Laboratories, Inc.
  • Dako (Agilent Technologies)
  • Danaher Corporation
  • Genomic Health
  • Laboratory Corporation of America (LabCorp)
  • MDxHealth
  • Myriad Genetics
  • QIAGEN
  • Roche
  • Siemens AG
  • Sysmex Corporation
  • Thermo Fisher Scientific
  • Other companies

This report discusses sales and recent performance analysis, key products, strengths and challenges, historical revenues, revenue forecast, market share forecast, mergers and acquisition (M&A) activity, strategic collaborations

Analysis of factors that drive and restrain the in vitro diagnostics (IVD) market.

Key Questions Answered by this Report:

  • Who are the leading IVD manufacturers?
  • What factors are driving and restraining growth for the leading IVD manufacturers?
  • How have the leading IVD manufacturers performed financially in recent years?
  • Which IVD manufacturers will experience revenue growth over the coming years?
  • What are the strength and weakness of the leading IVD manufacturers?
  • What strategies have IVD manufacturers been implementing for sales growth in recent years?

Visiongain's study is intended for anyone requiring commercial analyses for the leading in vitro diagnostics (IVD) companies. You find data, trends and predictions.

Buy our report today Medical Devices Leader Series: Top In Vitro Diagnostics (IVD) Companies 2019-2029: Danaher Corporation, Abbott Laboratories, Bio-Rad Laboratories, Roche, Siemens AG, Sysmex, Other Companies’.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 How This Report Delivers Information
  • 1.2 Main Questions This Report Answers
  • 1.3 Who is This Report for?
  • 1.4 Methods of Research and Analysis
  • 1.5 Frequently Asked Questions (FAQs)
  • 1.6 Associated Visiongain Reports
  • 1.7 About Visiongain

2. An Introduction to In Vitro Diagnostics

  • 2.1 The In Vitro Diagnostics Market
    • 2.1.1 The In Vitro Diagnostics Market in 2018
  • 2.2 What are In Vitro Diagnostic (IVD) Tests?
  • 2.3 Classifying In Vitro Diagnostics
    • 2.3.1 The US Classification
    • 2.3.2 The EC (European Commission) Classification
    • 2.3.3 Regulatory Issues in the IVD Market
      • 2.3.3.1 Regulation of IVD Tests
      • 2.3.3.2 Lack of Clarity Can Be Costly
  • 2.4 Types of IVD Test
    • 2.4.1 Point of Care Diagnostics
    • 2.4.2 Clinical Chemistry
    • 2.4.3 Microbiology
      • 2.4.3.1 Regulatory Differences with IVD Microbiology Tests
    • 2.4.4 Haematology
    • 2.4.5 Immunochemistry
    • 2.4.6 Genetic Testing
  • 2.5 The IVD Market: Overall Revenue Forecast to 2029
    • 2.5.1 Market Drivers, 2019-2029
    • 2.5.2 Market Restraints, 2019-2029
    • 2.5.3 Future of the IVD Industry
  • 2.6 Company Comparison
  • 2.6.1 Fragmented Market
  • 2.6.2 IVD Market: Leading Manufacturers in 2018

3. The Leading US in Vitro Diagnostic Companies, 2019-2029

  • 3.1 Danaher Corporation
    • 3.1.1 Sales and Recent Performance Analysis
    • 3.1.2 Diagnostics
    • 3.1.3 Key Products
    • 3.1.4 Danaher Manufacturing Capabilities
    • 3.1.5 Danaher IVD Segment: Strengths and Challenges
    • 3.1.6 Danaher's Life Sciences and Diagnostics Revenues
    • 3.1.7 IVD Revenue Forecast, 2018-2029
    • 3.1.8 Recent Mergers and Acquisition (M&A) Activity
  • 3.2 Abbott Laboratories
    • 3.2.1 Sales and Recent Performance Analysis
    • 3.2.2 Abbott: Diagnostics Segment
    • 3.2.2.1 In Vitro Diagnostics Products
    • 3.2.3 Abbott IVD Segment: Strengths and Challenges
    • 3.2.4 Abbott Diagnostics Historical Revenues, 2015-2017
    • 3.2.5 IVD Revenue Forecast, 2019-2029
    • 3.2.6 Recent M&A Activity and Strategic Collaborations
      • 3.2.6.1 Collaboration with GSK
      • 3.2.6.2 Collaboration with Merck
      • 3.2.6.3 Acquisition of Alere, Inc.
  • 3.3 Bio-Rad Laboratories, Inc.
    • 3.3.1 Sales and Recent Performance Analysis
    • 3.3.2 Clinical Diagnostics
      • 3.3.2.1 In Vitro Diagnostics
    • 3.3.3 IVD Revenue 2018
    • 3.3.4 IVD Revenue Forecast, 2019-2029
    • 3.3.5 Recent M&A Activity and Strategic Collaborations
    • 3.3.6 Potential Bio-Rad Labs Takeover Seen in Near-Term
  • 3.4 Becton, Dickinson and Company
    • 3.4.1 Global Presence
    • 3.4.2 Distribution
    • 3.4.3 R&D
    • 3.4.4 Sales and Recent Performance Analysis
      • 3.4.4.1 Historical Sales Performance Analysis
    • 3.4.5 BD Diagnostics Revenue
    • 3.4.6 IVD Revenue Forecast, 2019-2029
    • 3.4.7 Recent M&A Activity and Strategic Collaborations
  • 3.5 Thermo Fisher Scientific
    • 3.5.1 Historical Sales and Recent Performance Analysis
    • 3.5.2 Clinical Diagnostics
    • 3.5.3 Key Products
    • 3.5.4 Thermo Fisher's Manufacturing Capabilities
    • 3.5.5 Thermo Fisher's Diagnostics Revenues
    • 3.5.6 IVD Revenue Forecast 2019-2029
    • 3.5.7 Recent Mergers and Acquisition Activity

4. The Leading European In Vitro Diagnostic Companies, 2019-2029

  • 4.1 Hoffmann-La Roche Ltd.
    • 4.1.1 Global Presence
    • 4.1.2 Sales and Recent Performance Analysis
    • 4.1.3 Roche Diagnostics
    • 4.1.4 R&D Capabilities
    • 4.1.5 Growing Portfolio of Diagnostic Products
      • 4.1.5.1 Exploring Strategies in the Neurological Sector
    • 4.1.6 IVD Revenue Forecast 2019-2029
    • 4.1.7 Recent M&A Activity and Strategic Collaborations
  • 4.2 Siemens AG
    • 4.2.1 Sales and Recent Performance, 2017
    • 4.2.2 Siemens Healthcare
      • 4.2.2.1 Siemens Diagnostics
      • 4.2.2.2 Outperforming the Market
      • 4.2.2.3 In Vitro Diagnostics
    • 4.2.3 IVD Revenue Forecast 2019-2029
    • 4.2.4 Recent M&A Activity and Strategic Collaborations
      • 4.2.4.1 Partnership with ViiV Healthcare
      • 4.2.4.2 Partnership with Tocagen
      • 4.2.4.3 Acquisition of Fast Track Diagnostics
  • 4.3 bioMérieux S.A.
    • 4.3.1 Sales and Recent Performance, 2017
    • 4.3.2 IVD Revenue Forecast 2019-2029
    • 4.3.3 Recent M&A Activity and Strategic Collaborations
      • 4.3.3.1 Partnership with GSK
      • 4.3.3.2 Partnership with Ipsen
      • 4.3.3.3 Partnership with Institute Merieux and Institute Pasteur
      • 4.3.3.4 Collaboration with Hospices Civils de Lyon
      • 4.3.3.5 Acquisition of ARGENE
      • 4.3.3.6 Equity Interest in Knome

5. The Leading Japanese In Vitro Diagnostic Companies, 2019-2029

  • 5.1 Sysmex Corporation
    • 5.1.1 Global Presence and Distribution
    • 5.1.2 Sales and Recent Performance Analysis
    • 5.1.3 Sysmex Diagnostics
    • 5.1.4 IVD Revenue Forecast 2019-2029
    • 5.1.5 Recent M&A Activity and Strategic Collaborations
      • 5.1.5.1 Acquisition of Katakura's Research Institute of Biological Science
      • 5.1.5.2 Collaboration with IDEXX Labs to Expand into Animal Diagnostics
  • 5.2 Arkray, Inc.
    • 5.2.1 Global Presence
    • 5.2.2 R&D
    • 5.2.3 IVD Product Portfolio
    • 5.2.4 Sales and Recent Performance Analysis
    • 5.2.5 IVD Revenue Forecast 2019-2029

6. Emerging In Vitro Diagnostic Companies, 2018

  • 6.1 Pipeline and Other Companies: An Overview, 2018
  • 6.2 Other Prominent In Vitro Diagnostic Players
  • 6.3 Dako (Agilent Technologies)
    • 6.3.1 Sales and Recent Performance Analysis
    • 6.3.2 M&A Activity and Other Key Developments
  • 6.4 Genomic Health, Inc.
    • 6.4.1 Sales and Recent Performance Analysis
    • 6.4.2 R&D Capabilities
      • 6.4.2.1 TAILORx Clinical Trial
      • 6.4.2.2 RxPonder Trial
      • 6.4.2.3 Partnership with Oncomed
  • 6.5 Laboratory Corporation of America (LabCorp)
    • 6.5.1 Sales and Recent Performance Analysis
    • 6.5.2 In Vitro Diagnostics
  • 6.6 Recent M&A Activity and Other Key Developments
    • 6.6.1 Non-Exclusive License Agreement with Merck
    • 6.6.2 Acquisition of Genzyme Genetics
    • 6.6.3 Partnership with ARCA Biopharma
  • 6.7 MDxHealth, Inc.
    • 6.7.1 Sales and Recent Performance Analysis, 2017
    • 6.7.2 R&D Capabilities
    • 6.7.3 In Vitro Diagnostics
      • 6.7.3.1 PharmacoMDx
      • 6.7.3.2 PredictMDx for Brain Cancer
      • 6.7.3.3 PredictMDx for Colon Cancer
      • 6.7.3.4 Partnership with GSK
  • 6.8 Myriad Genetics, Inc.
    • 6.8.1 Sales and Recent Performance Analysis
    • 6.8.2 R&D Capabilities
    • 6.8.3 In Vitro Diagnostics
  • 6.8.3.1 Myriad RBM
    • 6.8.4 M&A Activity and Recent Partnerships
      • 6.8.4.1 Agreement with BioMarin Pharmaceutical
      • 6.8.4.2 Acquisition of Myriad RBM
      • 6.8.4.3 Strategic Debt Investment in Crescendo Bioscience
      • 6.8.4.4 Agreement with Cephalon
      • 6.8.4.5 Agreement with PharmaMar
  • 6.9 QIAGEN N.V.
    • 6.9.1 Sales and Recent Performance Analysis
    • 6.9.2 Continued Expansion in the Emerging Markets
    • 6.9.3 R&D Capabilities
      • 6.9.3.1 More than 15 Projects to Co-Develop and Market Diagnostic Products
      • 6.9.3.2 Provider of Choice for Molecular Diagnostic Tools
    • 6.9.4 Recent M&A Activity and Other Developments
      • 6.9.4.1 Acquisition of Cellestis Ltd.
      • 6.9.4.2 Acquisition of Ipsogen
      • 6.9.4.3 Partnership with Pfizer
      • 6.9.4.4 Partnership with Eli Lilly

7. Other In-Vitro Diagnostic Companies, 2018

  • 7.1 Hologic, Inc.
    • 7.1.1 Sales and Recent Performance Analysis
    • 7.1.2 In Vitro Diagnostics
    • 7.1.3 Recent M&A Activity and Strategic Collaborations
  • 7.2 Bayer AG
    • 7.2.1 Sales and Recent Performance Analysis
    • 7.2.2 In Vitro Diagnostics
    • 7.2.3 Recent M&A Activity and Strategic Collaborations
  • 7.3 Transasia Bio-Medicals Ltd.
    • 7.3.1 In Vitro Diagnostics
    • 7.3.2 Recent M&A Activity and Strategic Collaborations
  • 7.4 PerkinElmer, Inc.
    • 7.4.1 Sales and Recent Performance Analysis
    • 7.4.2 In Vitro Diagnostics
    • 7.4.3 Recent M&A Activity and Strategic Collaborations
  • 7.5 DiaSorin S.p.A.
    • 7.5.1 Sales and Recent Performance Analysis
    • 7.5.2 In Vitro Diagnostics
    • 7.5.3 Recent M&A Activity and Strategic Collaborations
  • 7.6 Koninklijke Philips N.V.
    • 7.6.1 Sales and Recent Performance Analysis
    • 7.6.2 In Vitro Diagnostics
    • 7.6.3 Recent M&A Activity and Strategic Collaborations
  • 7.7 Illumina, Inc.
    • 7.7.1 Sales and Recent Performance Analysis
    • 7.7.2 In Vitro Diagnostics
    • 7.7.3 Recent M&A Activity and Strategic Collaborations
  • 7.8 Kem-en-tec Diagnostics A/S
    • 7.8.1 In Vitro Diagnostics
    • 7.8.2 Recent M&A Activity and Strategic Collaborations

8. Conclusions

  • 8.1 In Vitro Diagnostics: Attractive Segment of the Healthcare Market
  • 8.2 Big Pharma Dominated the IVD Market in 2018
  • 8.3 The Rise of ‘Generic Medical Devices'
  • 8.4 What Will Succeed in the IVD Market?
  • 8.5 Small Companies Can Have a Big Impact on the Industry and Market to 2029

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form
Back to Top